Merck (MRK) reachead $117.17 at the closing of the latest trading day, reflecting a -0.05% change compared to its last close.

Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Barron's market reporter Jacob Sonenshine breaks down the market as the Fed meeting kicks off and spotlights pharmaceutical company Merck.

That increase has boosted valuations, as the price-to-sales (P/S) ratio of 19 indicates that the stock is not cheap. Still, considering that ServiceNow's average P/S ratio over the last five years is ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...